- 1 **Title:** Diagnostic serology test comparison for Q fever and Rift Valley fever in humans and livestock
- 2 from pastoral communities
- 3
- 4 **Authors:** Valerie Hungerbühler¹, Ranya Özcelik¹, Mahamat Fayiz Abakar², Fatima Abdelrazak
- 5 Zakaria², Martin Eiden³, Sonja Hartnack⁴, Pidou Kimala², Sonja Kittl⁵, Janine Michel⁶, Franziska
- 6 Suter-Riniker⁷, Salome Dürr¹
- 7 Affiliations
- 8 ¹Veterinary Public Health Institute, Vetsuisse Faculty, University of Bern, Bern, Switzerland
- 9 ²Institut de Recherche en Elevage pour le Développement, N'Djamena, Chad
- ³Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald Insel Riems,
- 11 Germany
- 12 ⁴Section of Epidemiology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
- 13 ⁵ZOBA, Center for Zoonoses, Animal Bacterial Diseases and Antimicrobial, Vetsuisse Faculty,
- 14 University of Bern, Bern, Switzerland
- 15 ⁶Robert Koch Institute, Centre for Biological Threats and Special Pathogens, Highly Pathogenic
- 16 Viruses, Berlin, Germany
- 17 ⁷IFIK, Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Bern, Switzerland
- 18
- 19 Correspondence: Valerie Hungerbühler
- 20 Veterinary Public Health Institute, Vetsuisse Faculty
- 21 University of Bern
- 22 Schwarzenburgstrasse 161
- 23 3097 Liebefeld, Switzerland
- 24 M: +41 77 423 18 62
- 25 E: <u>valerie.hungerbuehler@vetsuisse.unibe.ch</u>

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Abstract

28

Q fever (QF) and Rift Valley fever (RVF) are endemic zoonotic diseases in African countries, causing significant health and economic burdens. Accurate prevalence estimates, crucial for disease control, rely on robust diagnostic tests. While enzyme-linked immunosorbent assays (ELISA) are not the gold standard, they offer rapid, cost-effective, and practical alternatives. However, varying results from different tests and laboratories can complicate comparing epidemiological studies. This study aimed to assess the agreement of test results for QF and RVF in humans and livestock across different laboratory conditions and, for humans, different types of diagnostic tests.

We measured inter-laboratory agreement using concordance, Cohen's kappa, and prevalence and biasadjusted kappa (PABAK) on 91 human and 102 livestock samples collected from rural regions in Chad. The samples were tested using ELISA in Chad, and indirect immunofluorescence assay (IFA) (for human QF and RVF) and ELISA (for livestock QF and RVF) in Switzerland and Germany. Additionally, we examined demographic factors influencing test agreement, including district, setting (village vs. camp), sex, age, and livestock species of the sampled individuals.

The inter-laboratory agreement ranged from fair to moderate. For humans, QF concordance was 62.5%, Cohen's kappa was 0.31, RVF concordance was 81.1%, and Cohen's kappa was 0.52. For livestock, QF concordance was 92.3%, Cohen's kappa was 0.59, RVF concordance was 94.0%, and Cohen's kappa was 0.59. Multivariable analysis revealed that QF test agreement is significantly higher in younger humans and people living in villages compared to camps and tends to be higher in livestock from Danamadji compared to Yao, and in small ruminants compared to cattle. Additionally, RVF agreement was found to be higher in younger humans.

49 Our findings emphasize the need to consider sample conditions, test performance, and influencing
50 factors when conducting and interpreting epidemiological seroprevalence studies.

52 Author Summary

53

54 Q fever (QF) and Rift Valley fever (RVF) are zoonotic diseases that can be transmitted from animals to humans, causing health problems and economic losses in African countries. While various diagnostic 55 tests for these diseases are available, they can be impractical, especially in resource-limited settings. 56 57 For this study, human and livestock samples from Chad were first tested in a local laboratory using a 58 routine test. The same samples were then sent to laboratories in Germany or Switzerland for retesting, 59 using the same test type for livestock and a different test type for human samples. 60 We analysed the agreement between the test results and investigated the influence of the demographic characteristics of the sampled individual on this agreement. Our findings are crucial as they reveal 61 62 discrepancies in test results, even though the samples originated from the same individuals. Additionally, we found that factors such as the age of the sampled individual influenced test agreement. 63 This study underscores the importance of considering sample conditions, test performance, and 64 influencing factors when conducting and interpreting disease prevalence studies. Enhancing diagnostic 65 66 procedures will aid in more effective disease control management, benefiting local communities and 67 global health efforts.

69 1. Introduction

70

Q Fever (QF) and Rift Valley fever (RVF) are zoonotic diseases prevalent in several African countries.
Reported prevalence rates range from 7.8% to 39% for QF and 9.5% to 44.2% for RVF in livestock, and
from 27% to 49.2% for QF and 13.2% to 28.4% for RVF in humans [1–4]. QF and RVF impact human
health by causing a flu-like syndrome that can lead to a range of severe manifestations. QF and RVF
also result in significant production losses in animals due to abortions [5,6].

High-quality samples and robust diagnostic tests are essential for obtaining accurate prevalence estimates. Epidemiological studies play a critical role in generating the necessary data, subsequently influencing government prioritization of health interventions [7,8]. This prioritization is fundamental to effective disease control.

For QF diagnostics, the indirect immunofluorescence assay (IFA) can differentiate between acute and 80 chronic infections and is regarded as the gold standard test for humans [9,10]. Commercial kits are not 81 82 available for veterinary use [11]. The enzyme-linked immunosorbent assay (ELISA) is the most widely 83 used test and is recommended by the WOAH (World Organisation for Animal Health) for rapid routine 84 screening and large-scale epidemiological studies in ruminant populations [8]. For RVF, the virus 85 neutralisation test (VNT) is the most specific diagnostic serological test, but it can only be performed with live viruses and is not recommended for use in laboratories without appropriate biosecurity 86 87 facilities and vaccinated personnel [6,7]. For both diseases, ELISAs offer a rapid, cost-effective, and 88 practical alternative with less stringent biosafety requirements, making them suitable for routine use in 89 low- and middle-income countries (LMIC) [7,8].

The use of ELISA in some studies and the gold standard test, which may differ between countries, in others can lead to discrepancies in estimated prevalence, making comparisons challenging; thus, harmonized monitoring and reporting schemes for QF and RVF have been proposed to enable consistent comparisons over time and across countries [12–14].

94 Several studies have assessed the inter-test agreement of ELISA for QF and RVF compared to other 95 diagnostic tests, reporting variable agreement ranging from poor to good for QF and from good to 96 excellent for RVF [15–21]. Diagnostic test validation can be achieved through various methods,

97 including assessing the agreement between different tests without assuming one as the gold standard [22]. Concordance, the proportion of test results in agreement over the number of all tests performed, is 98 99 a straightforward measure but does not account for agreement beyond chance. Therefore, Cohen's kappa 100 statistic, which adjusts for random matches, is often used to measure the agreement between two test 101 results [22]. Cohen's kappa values range from zero (agreement is equal to that expected by chance) to 102 one (complete agreement beyond chance), with benchmarks between agreement categories varying 103 among authors [23–25]. Although Cohen's kappa is a standard measure, it has limitations such as 104 prevalence and bias effects. Prevalence effects arise when the proportion of positive results deviates 105 significantly from 50% [26]. The effect of prevalence depends on the method of modeling agreement 106 and can substantially reduce kappa values [26]. Bias effects occur when there is a disparity in the 107 proportion of positive results between the two tests, which leads to reduced kappa values [26]. To address these effects, the prevalence- and bias-adjusted kappa (PABAK) can be calculated [27,28]. 108

109 The reasons for disagreement between diagnostic tests have rarely been thoroughly investigated. 110 Potential factors include poor sample quality, variability in tests used, and discrepancies arising from 111 the same test being conducted in different laboratories [17,21,29]. Additionally, biological factors such 112 as age, sex, other diseases, and species may influence the consistency of test results for the same sample. 113 Previous studies have suggested associations between test performance and variables such as region, 114 age, and livestock species [30–32]. However, these studies have not provided conclusive evidence or 115 statistical significance.

116 The objective of this study was to assess the inter-laboratory agreement, measured by the concordance, 117 Cohen's kappa, and PABAK, of results obtained from commercial ELISA tests conducted in a laboratory in Chad and results obtained from ELISA and indirect IFA tests for livestock and human samples 118 119 respectively, performed in laboratories in Germany and Switzerland. Additionally, we evaluated the 120 influence of demographic factors on the agreement between the two test results. The study enhances our understanding of the inter-laboratory agreement of diagnostic test results across laboratory conditions 121 122 and, for humans, test types, which is crucial for accurately interpreting results from epidemiological 123 seroprevalence studies.

124 2. Material and Methods

125

126 2.1 Ethics statement

127 The study has been submitted to and approved by the Ethics Committee of Northwest and Central 128 Switzerland (EKNZ) (project id 2017-00884) and by the Comité National de Bioéthique du Tchad 129 (CNB-Tchad) (project id 134/PR/MESRS/CNBT/2018). Formal written consent was obtained from 130 study participants and animal owners after we presented our study to the community and before data 131 collection occurred.

132

133 2.2 Sample collection and laboratory analysis in Chad

The samples analysed in this study were collected between January and February 2018 [4]. In brief, a 134 135 cross-sectional study in livestock (cattle, sheep, goats, horses, and donkeys) and human populations was conducted in the two rural health districts, Yao and Danamadji, in Chad. Multistage cluster sampling 136 137 was used, with villages and nomadic camps serving as cluster units. In Danamadji and Yao, respectively, 138 blood samples were collected from apparently healthy 571 and 389 humans and 560 and 483 livestock. 139 The samples were subsequently analysed at the Institut de Recherche en Élevage pour le Développement 140 (IRED) in N'Djamena, Chad. Livestock and human samples were analysed using different indirect ELISAs: ID Screen® Q Fever Indirect Multi-species ELISA from IDvet for livestock and the Panbio® 141 142 Coxiella burnetii IgG ELISA from Abbott for humans. For RVF, a competitive ELISA (ID Screen® 143 Rift Valley Fever Competition Multi-species from IDvet) was used for human and livestock samples. 144 The diagnostic test procedure and thresholds were applied according to the manufacturer's protocols without modification (Table S1 – Table S3). Equivocal samples were retested once. 145


146

147 2.3 Diagnostic testing in Switzerland and Germany


Following the initial diagnostic analysis at IRED, 10% of the human and livestock samples from each
region were randomly selected and sent to laboratories in Switzerland and Germany in 2021 for repeated
diagnostic analysis for QF and RVF, respectively. In Switzerland, two indirect ELISAs (IDEXX Q Fever
IgG Antibody and ID Screen® Q Fever Indirect Multispecies from IDvet) were used at the Center for

Zoonoses, Animal Bacterial Diseases, and Antimicrobial Resistance (ZOBA) for QF diagnostics in 152 livestock samples (ruminants and equids, respectively). At the Institute for Infectious Diseases (IFIK) 153 154 of the University of Bern, an indirect IFA (Q Fever IFA IgG assay from Focus Diagnostics, US) was used for QF diagnostics in human samples. For RVF, livestock samples were analysed using a 155 competitive ELISA (ID Screen® Rift Valley Fever Competition Multi-species ELISA from IDvet) at 156 the Federal Research Institute for Animal Health (FLI), and human samples were analysed using an 157 158 indirect IFA (Anti-Rift-Tal-Fieber-Viren-IIFT [IgG] from EUROIMMUN) at the Robert Koch Institute 159 (RKI). The diagnostic test procedure and thresholds were applied according to the manufacturer's protocols without modification (Table S1, Table S3, Table S4 – Table S6). Equivocal samples were not 160 161 retested.

162



163



165 Germany. The numbers of samples at each stage are indicated.

166

167 2.4 Statistical analysis

The inter-laboratory agreement of the test results from Chad and Switzerland or Germany was evaluated using concordance, Cohen's Kappa, and PABAK for each of the four datasets: QF results in human samples, QF results in livestock samples, RVF results in human samples, and RVF results in livestock samples. Cohen's kappa and PABAK values were interpreted according to the standard scale: 'fair' agreement (kappa = 0.21-0.40), 'moderate' agreement (kappa = 0.41-0.60), 'substantial' agreement (kappa = 0.61-0.80), and 'almost perfect' agreement (kappa > 0.80) [25].

174 In addition, we investigated factors associated with test agreement by assigning to each sample a value 175 of 0 if there was disagreement between the two test results (i.e., negative in Chad and positive in 176 Switzerland/Germany, or the opposite) and 1 if the test results were consistent (i.e., both positive or both 177 negative). This binary outcome was used as the dependent variable in logistic regression models to 178 identify the statistical association between test agreement and demographic factors, including the district 179 (Yao versus Danamadji) and setting (village versus camp) where the sample was collected, and sex, age, and livestock species (cattle, small ruminants, and equids) of the sampled individual. The variable age 180 181 was analysed in two ways, as a continuous and as a categorical variable. For the continuous variable, a 182 unit of 1 year was used for livestock and of 10 years for humans. For the categorical variable, samples 183 were stratified as < 2 years (age group 1), 2–3 years (age group 2), 4 years and older (age group 3) for livestock, and < 30 years (age group 1), 30–39 years (age group 2), 40–60 years (age group 3), 61 years 184 and older (age group 4) for humans. 185

Univariable logistic regressions were initially performed to assess individual predictors. In cases where the univariable model was infeasible due to perfect agreement in one group, Chi-square tests were applied. Odds ratios (OR) and their corresponding 95% confidence intervals were calculated for these analyses. To consider potential interdependencies between the variables, we applied multivariable logistic regressions to estimate adjusted coefficients and OR. We included all variables and selected age as categorical variable.

Statistical calculations, modeling, and data visualization were conducted in R (version 4.2.2). The package "irr" was used to calculate the concordance and Cohen's kappa. The package "vcd" was used to obtain confidence intervals of Cohen's kappa, computed using the standard method based on normal approximation [33]. The epi.kappa() function from the "epiR" package was used to calculate PABAK

- and corresponding confidence intervals. The confidence intervals for the OR were calculated using the
- 197 output values of the associated regression model and the functions exp(coefficients(model)) for the
- 198 upper CI and exp(confint.default(model)) for the lower CI was used.

Results

201

202 3.1 Study population and samples

From 103 livestock and 96 human samples sent to Switzerland and Germany, not all of them could be
used for statistical analysis. Reasons for excluding them include unsuccessful matching of test identity
due to labelling errors, missing serum upon arrival at the laboratory, and equivocal results (Table1).
Finally, 91 human and 102 livestock samples were tested for either one of both tests, depending on the
availability of serum (Table S7 and Table 1, Fig. 1).

208

209 Table 1: Overview of diagnostic tests from Chad and Switzerland (CH) or Germany (GE).

Disease	Q	F ¹	R	VF ²
Samples	Livestock	Humans	Livestock	Humans
Laboratory, Chad	IRED ³	IRED ³	IRED ³	IRED ³
Test 1, Chad	ID Screen [®] Q Fever	Panbio [®] Coxiella	ID Screen [®] Rift Valley	ID Screen [®] Rift Valley
	Indirect Multi-	burnetii IgG ELISA	Fever Competition	Fever Competition
	Species		Multi-species	Multi-species
Laboratory, CH/GE	ZOBA (CH) ⁴	IFIK (CH) ⁵	FLI (GE) ⁶	RKI (GE) ⁷
Test 2, CH/GE	IDEXX Q Fever Ab	Focus Diagnostics Q	ID Screen [®] Rift Valley	Indirect
	Test and the ID	Fever IFA IgG assay	Fever Competition	immunofluorescence
	Screen [®] Q Fever		Multi-species	test (IIFT)
	Indirect Multispecies			
Initial number of	103	96	103	96
samples shipped to				
CH/GE				
Excluded samples	2	8	0	4
from test 2 due to				
missing serum				
Equivocal results	8	14	2	0
during test 2				
Non-matchable	2	2	1	2
Number of samples	91	72	100	90
used for agreement				
testing				

210 ¹Q Fever

211 ²Rift Valley Fever

212 ³Institut de Recherche en Elevage pour le Développement, Chad

213 ⁴Center for Zoonoses, Animal Bacterial Diseases and Antimicrobial, Switzerland (CH)

- 214 ⁵Institute for Infectious Diseases, Switzerland (CH)
- 215 ⁶Friedrich-Loeffler-Institut, Germany (GE)
- 216 ⁷Robert Koch Institut, Germany (GE)
- 217

218 Of the 91 human and 102 livestock samples that were used to perform the intra-laboratory test agreement analysis, most samples were collected in Danamadji, with 62% of human samples and 57% of livestock 219 220 samples originating from this region (Table S7). Fifty-six percent of human samples and 58% of 221 livestock samples were collected from camps. The sex distribution was uneven, with 70% of human samples being men and 70% of livestock samples being females. Among humans, age groups 1-3 were 222 223 evenly represented (30%, 28%, 33%), while only 9% belonged to age group 4. In livestock, 50% of the samples were from age group 2, with 17% and 33% from age groups 1 and 3, respectively. Most 224 225 livestock samples were from cattle (46%), followed by small ruminants (41%) and equids (13%). 226 Diagnostic tests agreement 227 3.2

228 3.2.1 Level of inter-laboratory test agreement

Concordance values ranged from 62.5% to 94% (Table 2). Cohen's kappa values, which ranged from
0.31 to 0.59, indicated that livestock QF and RVF, and human RVF tests had 'moderate' agreement,
while human QF tests had 'fair' agreement (Table 2). PABAK values showed that the livestock QF and
RVF tests had 'almost perfect' agreement, the human RVF test had 'substantial' agreement, and the
human QF tests had 'fair' agreement (Table 2).

- 235 Table 2: Analyses of test agreement (concordance and Cohen's kappa) of samples tested in an inter-
- 236 laboratory test agreement study.

		Swit	zerland			Ge	rmany	
	QF I	ivestock	QF	humans	RVI	F livestock	RVF	humans
Chad	Pos	Neg	Pos	Neg	Pos	Neg	Pos	Neg
Pos	6	3	22	3	5	4	16	9
Neg	4	78	24	23	2	89	8	57
Concordance	92.3		62.5		94.0		81.1	
(%)								
Cohen's kappa	0.59 (0.31	., 0.86)	0.31 (0.1	3, 0.49)	0.59 (0.3	80, 0.89)	0.52 (0.3	33, 0.72)
value (95% CI)								

	PABAK value (95% Cl)	0.846 (0.696, 0.937)	0.25 (0.006, 0.473)	0.88 (0.748, 0.955)	0.622 (0.43, 0.771)
237	. ,				
238					
239	3.2.1 Influence	ce of factors on inter-	aboratory test agreen	nent	
240	For QF in livest	ock, none of the inves	stigated demographic	factors significantly in	mpacted the agreement
241	between the two	o test results in both	univariable and mul	tivariable analyses (T	Table S8 and Table 3).
242	However, some	notable trends ($p < 0$	0.15) emerged: small	ruminants tended to	show better agreement
243	than cattle, and	samples from Yao sh	owed lower agreemen	nt compared to those f	rom Danamadji (Table
244	3). For QF in hu	mans, samples from v	villages had significan	tly higher agreement o	compared to those from
245	camps, with odd	ds of agreement being	g 13.4 times higher (Table 3). Additionally	v, older age groups had
246	significantly lower agreement compared to the youngest age group (Table 3).				
247	For RVF in humans and livestock, none of the demographic factors significantly influenced test				
248	agreement. However, some trends were observed for RVF test agreement in humans, with older age				
249	groups showing	lower agreement con	npared to the younges	st age group (Table 3)	
250	Across diseases	and populations, the	re was a consistent tr	end of lower agreeme	nt with increasing age,
251	which was signi	ificant for human QF	and almost reached s	ignificance for human	RVF (Table 3, Fig. 2).
252	For livestock R	VF tests, the odds rat	io for agreement was	also lower in older ag	ge groups, although the
253	p-value was 0.2	6 (Table 3).			
254	Table 3: Results	of multivariable logist	tic regression models i	nvestigating the effect	of demographic factors

- as independent variables on the inter-laboratory test agreement of Q fever (QF) and Rift Valley Fever
- 256 (RVF) in humans and livestock. Goodness of fit of the models are presented as pseudo-R-squared (R²).
- 257 Bold p-values indicate significance based on a threshold of 0.05.


	Swit	tzerland	Ge	rmany
	QF livestock QF humans		RVF livestock	RVF humans
Independent variable (OR and 95% CI)				
P-value (P)				
District	Yao:	Yao:	Yao:	Yao:
(Reference:	0.14 (0.01, 1.74)	1.38 (0.38, 4.99)	4.99 (0.41, 60.49)	1.37 (0.37, 5.04)
Danamadji)	P = 0.13	P = 0.63	P = 0.21	P = 0.64

Setting	Village:	Village:	Village:	Village:
(Reference: camp)	0.34 (0.05, 2.06)	13.35 (3.20, 55.86)	0.32 (0.04, 2.43)	1.85 (0.58, 5.93)
	P = 0.24	P = 0.0004	P = 0.27	P = 0.30
Species	Equids:	-	Equids:	-
(Reference: cattle)	5.51 (0.29, 103.21)		Inf (perfect	
	P = 0.25		agreement)	
	Small ruminants:		Small ruminants:	
	6.26 (0.59, 65.76)		0.65 (0.09, 4.78)	
	P = 0.13		P = 0.67	
Age group	Group 2:	Group 2:	Group 1*:	Group 2:
(Reference: age	1.30 (0.10, 17.39)	0.67 (0.15, 3.07)	Inf (perfect	0.62 (0.12, 3.16)
group 1/group 2*)	P = 0.84	P = 0.61	agreement)	P = 0.57
group 1/group 2 /	1 - 0.04	1 - 0.01	agreementy	1 - 0.37
	Group 3:	Group 3:	Group 3*:	Group 3:
	0.93 (0.06, 14.38)	0.14 (0.03, 0.82)	0.30 (0.04, 2.41)	0.32 (0.07, 1.47)
	P = 0.96	P = 0.03	P = 0.26	P = 0.14
		Group 4:		Group 4:
		0.09 (0.01, 0.83)		0.16 (0.02, 1.14)
		P = 0.03		P = 0.07
Sex	Female:	Female:	Female:	Female:
(Reference: male)	0.38 (0.03, 4.61)	0.82 (0.20, 3.38)	0 (perfect agreement	1.01 (0.27, 3.86)
	P = 0.45	P = 0.78	in males)	P = 0.99
-1				
R ²	0.23	0.35	0.28	0.09


diagnostic test results


concordant

discrepant



261





Livestock: Agreement RVF ~ Age Group

262

Fig. 2: In the mosaic plot illustrating the association between age groups and inter-laboratory test agreement, the widths of the adjacent rectangles represent the proportion of individuals within each age group. The heights of the rectangles represent the proportion of individuals within each age group who exhibit a specific test agreement outcome (concordant or discrepant).

268 4. Discussion

269

QF and RVF are important zoonotic diseases in sub-Saharan Africa, for which several epidemiological
questions remain open. Reliable diagnostics are highly relevant for generating prevalence data, and it
has been emphasized that there is a need for cost-effective surveillance tools for low and middle-income
countries [5,34].

274 Our study revealed varying levels of test agreement, ranging from fair to moderate (Cohen's kappa) or 275 almost perfect when considering PABAK. The good inter-laboratory agreement of livestock test results 276 for RVF was in line with other studies on RVF test agreement, although it is important to note that literature is scarce [19,20]. The inter-laboratory agreement for livestock QF was slightly better than 277 278 expected, based on previous studies that assessed ELISA's agreement with different test types [15,17,18]. We observed a notably lower agreement for human tests for both diseases that can be 279 280 attributed to using two different tests for human samples, ELISA in Chad and indirect IFA in 281 Switzerland or Germany. Previous studies have shown varying sensitivities and specificities of the 282 commercial diagnostic test for QF used in this study (Panbio®), ranging from 71% to 100% [10,35-37]. 283 In these studies, indirect IFA was used as a reference method to evaluate the ELISA, revealing varying 284 agreement between the results of the two tests. The variability in sensitivity for the same test raises the question of whether it is due to the scope for interpretation in indirect IFA, which is considered a 285 286 challenge, even though indirect IFA is regarded as the gold standard for human QF diagnostics [5,8]. A 287 study that compared QF indirect IFA results from different reference centres in three countries (United 288 Kingdom, France, and Australia) found a concordance between the indirect IFA results of only 35% [38]. Our results presented here reflect this uncertainty and underline the complexity of QF diagnostics 289 290 [5,8,39]. In addition, commercial QF ELISA kits, unlike indirect IFA, cannot distinguish between acute 291 or chronic infection and vaccination, which can sometimes lead to misinterpretation and discordant test results, even between different ELISA kits [21,40]. For RVF, lower inter-laboratory agreement for 292 293 human tests compared to livestock tests can also be attributed to using different tests in Chad (ELISA) and Germany (indirect IFA). The literature on RVF test agreement, particularly for human diagnostics, 294 295 is notably scarce.

296 A possible reason for disagreement between test results could be the hemolytic quality of some of our 297 samples. Although we lack quantitative information on the quality of the individual samples in our study, 298 laboratory staff in Switzerland and Germany indicated that haemolysis was a concern. In recent 299 literature, haemolysis in specimens was reported to be the most common cause of test result discrepancies in clinical laboratories [41]. There are many in vitro causes of haemolysis, mostly pre-300 301 analytical problems such as incorrect procedures and/or materials used in blood collection, while 302 transport, processing, and storage account for only a minority of cases [42]. This limitation shows the 303 importance of careful planning and execution of the pre-analytical phase, especially in prevalence 304 studies where the outcome can be influenced by the quality of the sample material. Nevertheless, it is 305 crucial to recognize the challenges associated with collecting samples under difficult field conditions, 306 where access to centrifuges may be limited until several days after blood sampling. In addition, the 307 samples in our study were stored for 2.5 years with repeated freeze-thaw cycles between the performance of the two tests for some of the samples, which probably affected sample quality. Therefore, extended 308 309 transport to secondary laboratories for subsequent analysis can additionally adversely affect sample 310 quality. We emphasize the importance of considering these challenges when discussing the outcomes of 311 epidemiological prevalence studies or diagnostic test evaluation studies.

312 Our results demonstrate a statistical relationship between test agreement and age of the sampled individuals, with higher agreement observed in younger individuals for both diseases and in humans and 313 314 livestock. This finding aligns with a study by de Bronsvoort et al. (2019), which suggested that lower 315 agreement in older individuals may be due to their higher likelihood of previous exposure to other 316 pathogens over their lifetime [30]. This may result in cross-reactivity in serological tests, making serological differentiation between diseases more difficult [39]. Cross-reactions caused by antibodies 317 provoked by other pathogens, such as C. burnetii antigens, the agent causing QF, with antibodies 318 319 produced against Bartonella spp., Legionella spp., and Chlamydiae spp. has been reported [43–45], or 320 RVF virus antigens with antibodies produced against Rio Grande virus [46-48]. Furthermore, with increasing age, the likelihood of exposure to the causative agent of QF and RVF increases [49,50], as 321 does the chance of having residual antibodies titres against these diseases in the blood [6,51-53].In 322 addition in OF, antigen-lipopolysaccharide complexes remaining in the host after infection with C. 323

burnetii can trigger humoral and cell-mediated immune responses, producing interfering antibodies [54,55]. Such antibody titres can potentially produce ambiguous results that are neither clearly positive nor negative, leading to misinterpretation and discordant test results. These findings underscore the need for further research to develop age-specific diagnostic protocols and improve test accuracy across diverse populations.

The district-level analysis showed a trend toward higher agreement for livestock QF tests in samples 329 330 from Danamadji compared to Yao. This regional variation may be influenced by varying local 331 environmental conditions, disease prevalence, or livestock management practices. However, we did not capture such information, so we were not able to identify a potential latent factor that can explain the 332 333 difference in test agreement detected for the two regions. Continuing with the focus on sampling 334 location, the sample collection setting (village versus camp) was identified as a significant factor in the multivariable model for human QF test agreement. One hypothesis for this finding is that villages 335 generally have shorter distances from the sampling location to the laboratory, allowing for more 336 337 appropriate storage conditions compared to remote camps. This shorter travel time likely preserves 338 sample integrity, resulting in higher test agreement. The significant role of the setting variable suggests 339 that environmental and logistical factors may be crucial for diagnostic test result interpretation, although 340 we did not observe the influence of the setting for RVF in humans nor for livestock species. Future studies should investigate the impact of environmental and logistical factors on test results and gather 341 342 detailed data on local conditions and practices that affect sample quality and test agreement.

Small ruminants exhibited a trend towards higher agreement in QF test results compared to cattle. In a different type of QF ELISA, Stellfeld et al. (2020) observed significant differences in the ranges of OD_{450} values obtained from sera of sheep, goats, and cattle [56]. Sheep exhibited a large range of OD_{450} values, whereas cattle showed a smaller range [56]. Greater distribution between OD_{450} values allows for more precise grading of ELISA results, which may explain the better inter-test agreement for small ruminants compared to cattle. These differences in OD_{450} ranges are likely due to species-specific immune responses to *C. burnetii*, suggesting varying immune reactions among ruminant species [56].

350 Although females showed lower inter-laboratory test agreement compared to males for both diseases 351 and populations, the high p-values and wide confidence intervals of OR indicate that these results are

- 352 not statistically robust and should be interpreted with caution. Epidemiological studies suggest similar
- 353 QF exposure rates between genders, but symptoms are 2.5 times more common in men [5]. This
- variability in inflammatory immune response between genders [57–60] could lead to less clear antibody
- 355 titers in samples from females, a hypothesis that should be tested by further studies investigating the
- 356 influence of demographic factors on diagnostic test agreement.

357 Conclusion

Our study highlights the variability in inter-laboratory diagnostic test agreement for QF and RVF serology in humans and livestock based on samples collected in Chad. Despite differences in laboratories, personnel, and test types, test agreements ranged from fair to moderate (Cohen's kappa) or almost perfect considering PABAK. Given the reliance on serological profiles for QF and RVF epidemiological studies, it is crucial to consider factors that may complicate accurate diagnosis. We identified that human QF test agreement was significantly higher in individuals living in villages and younger individuals, with the latter trend also observed in human RVF tests. Our findings emphasize the need to recognize that diagnostic tests may yield varying results, impacting the outcome and interpretation of disease prevalence studies.

377	Decla	ration of generative AI and AI-assisted technologies in the writing process
378		
379	While	preparing this work, the author used ChatGPT to correct the English in the revised sentences
380	(using	the command: 'correct the English'). After using this tool, the author reviewed and edited the
381	conter	nt as needed and takes full responsibility for the content of the publication.
382		
383	Refere	ences
384		
385 386 387	[1]	Fayiz Abakar M, Naré NB, Schelling E, Hattendorf J, Alfaroukh IO, Zinsstag J. Seroprevalence of Rift Valley fever, Q fever, and brucellosis in ruminants on the southeastern shore of Lake Chad. Vector-Borne and Zoonotic Diseases 2014;14: 757–62. doi: 10.1089/VBZ.2014.1585.
388 389 390	[2]	Blomström AL, Scharin I, Stenberg H, Figueiredo J, Nhambirre O, Abilio A, et al. Seroprevalence of Rift Valley fever virus in sheep and goats in Zambézia, Mozambique. Infect Ecol Epidemiol 2016;6. doi: 10.3402/IEE.V6.31343.
391 392 393	[3]	Ibrahim M, Schelling E, Zinsstag J, Hattendorf J, Andargie E, Tschopp R. Sero-prevalence of brucellosis, Q-fever and Rift Valley fever in humans and livestock in Somali Region, Ethiopia. PLoS Negl Trop Dis 2021;15: 1–18. doi: 10.1371/JOURNAL.PNTD.0008100.
394 395 396 397	[4]	Özcelik R, Abakar MF, Counotte MJ, Zakaria FA, Kimala P, Issa R, et al. Seroprevalence and associated risk factors of brucellosis, Rift Valley fever and Q fever among settled and mobile agro-pastoralist communities and their livestock in Chad. PLoS Negl Trop Dis 2023;17: e0011395. doi: 10.1371/JOURNAL.PNTD.0011395.
398 399 400	[5]	Eldin C, Mélenotte C, Mediannikov O, Ghigo E, Million M, Edouard S, et al. From Q fever to Coxiella burnetii infection: A paradigm change. Clin Microbiol Rev 2017;30: 115–90. doi: 10.1128/CMR.00045-16.
401 402	[6]	Wright D, Kortekaas J, Bowden TA, Warimwe GM. Rift Valley fever: biology and epidemiology. J Gen Virol 2019;100: 1187–99. doi: 10.1099/JGV.0.001296.
403 404	[7]	Rift Valley fever - WOAH - World Organisation for Animal Health [cited 17 June 2024]. Available from: https://www.woah.org/en/disease/rift-valley-fever/.
405 406	[8]	Q fever - WOAH - World Organisation for Animal Health [cited 17 June 2024]. Available from: https://www.woah.org/en/disease/q-fever/.
407 408	[9]	Imbert G, La Scola B. Diagnosis of Q fever using indirect microimmunofluorescence. Methods Mol Biol 2006;345: 197–202. doi: 10.1385/1-59745-143-6:197.
409 410 411	[10]	Dangel L, Koempf D, Fischer SF. Comparison of different commercially available enzyme- linked immunosorbent assays with immunofluorescence test for detection of phase II IgG and IgM antibodies to coxiella burnetii. J Clin Microbiol 2020;58. doi: 10.1128/JCM.00951-19.

412 [11] Wood C, Muleme M, Tan T, Bosward K, Gibson J, Alawneh J, et al. Validation of an indirect 413 immunofluorescence assay (IFA) for the detection of IgG antibodies against Coxiella burnetii in 414 bovine serum. Prev Vet Med 2019;169: 104698. doi: 10.1016/J.PREVETMED.2019.104698. 415 Wilson WC, Weingartl HM, Drolet BS, Davé K, Harpster MH, Johnson PA, et al. Diagnostic [12] 416 Approaches for Rift Valley Fever. Dev Biol (Basel) 2013;135: 73-8. doi: 10.1159/000276828. 417 [13] Gerken KN, Labeaud AD, Mandi H, Jackson ML, Breugelmans JG, King CH. Paving the way for 418 human vaccination against Rift Valley fever virus: A systematic literature review of RVFV 419 epidemiology from 1999 to 2021. PLoS Negl Trop Dis 2022;16. doi: 420 10.1371/JOURNAL.PNTD.0009852. 421 [14] Sidi-Boumedine K, Rousset E, Henning K, Ziller M, Niemczuck K, Roest H, et al. Development of 422 harmonised schemes for the monitoring and reporting of Q-fever in animals in the European 423 Union. EFSA Supporting Publications 2017;7. doi: 10.2903/SP.EFSA.2010.EN-48. 424 [15] Sadiki V, Gcebe N, Mangena ML, Ngoshe YB, Adesiyun AA. Prevalence and risk factors of Q 425 fever (Coxiella burnetii) in cattle on farms of Limpopo province, South Africa. Front Vet Sci 426 2023;10: 1101988. doi: 10.3389/FVETS.2023.1101988/BIBTEX. 427 Natale A, Bucci G, Capello K, Barberio A, Tavella A, Nardelli S, et al. Old and new diagnostic [16] 428 approaches for Q fever diagnosis: Correlation among serological (CFT, ELISA) and molecular 429 analyses. Comp Immunol Microbiol Infect Dis 2012;35: 375–9. doi: 430 10.1016/J.CIMID.2012.03.002. 431 Kittelberger R, Mars J, Wibberley G, Sting R, Henning K, Horner GW, et al. Comparison of the [17] 432 Q-fever complement fixation test and two commercial enzyme-linked immunosorbent assays 433 for the detection of serum antibodies against Coxiella burnetii (Q-fever) in ruminants: 434 Recommendations for use of serological tests on imported animals in New Zealand. N Z Vet J 2009;57: 262-8. doi: 10.1080/00480169.2009.58619. 435 436 [18] Rousset E, Durand B, Berri M, Dufour P, Prigent M, Russo P, et al. Comparative diagnostic 437 potential of three serological tests for abortive Q fever in goat herds. Vet Microbiol 2007;124: 438 286-97. doi: 10.1016/J.VETMIC.2007.04.033. 439 [19] Kortekaas J, Kant J, Vloet R, Cêtre-Sossah C, Marianneau P, Lacote S, et al. European ring trial 440 to evaluate ELISAs for the diagnosis of infection with Rift Valley fever virus. J Virol Methods 441 2013;187: 177-81. doi: 10.1016/J.JVIROMET.2012.09.016. 442 [20] Pawęska JT, van Vuren PJ, Msimang V, Lô MM, Thiongane Y, Mulumba-Mfumu LK, et al. Large-443 Scale International Validation of an Indirect ELISA Based on Recombinant Nucleocapsid 444 Protein of Rift Valley Fever Virus for the Detection of IgG Antibody in Domestic Ruminants. Viruses 2021;13. doi: 10.3390/V13081651. 445 446 [21] Horigan MW, Bell MM, Pollard TR, Sayers AR, Pritchard GC. Q fever diagnosis in domestic 447 ruminants: comparison between complement fixation and commercial enzyme-linked 448 immunosorbent assays. J Vet Diagn Invest 2011;23: 924–31. doi: 449 10.1177/1040638711416971. 450 Thrusfield M, Christley R, Brown H, Diggle PJ, French N, Howe K, et al. Veterinary [22] 451 Epidemiology: Fourth Edition. Veterinary Epidemiology: Fourth Edition 2017: 1–861. doi: 452 10.1002/9781118280249.

453	[23]	Fleiss JL, Levin B, Cho Paik M. Statistical Methods for Rates and Proportions, Third Edition.
454		Statistical Methods for Rates and Proportions, Third Edition 2004: 1–760. doi:
455		10.1002/0471445428.

- 456 [24] Altman DG. Practical Statistics for Medical Research. Practical Statistics for Medical Research
 457 1990. doi: 10.1201/9780429258589.
- 458 [25] Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.
 459 Biometrics 1977;33: 159. doi: 10.2307/2529310.
- 460 [26] Hoehler FK. Bias and prevalence effects on kappa viewed in terms of sensitivity and
 461 specificity. J Clin Epidemiol 2000;53: 499–503. doi: 10.1016/S0895-4356(99)00174-2.
- 462 [27] Byrt T, Bishop J, Carlin JB. Bias, prevalence and kappa. J Clin Epidemiol 1993;46: 423–9. doi:
 463 10.1016/0895-4356(93)90018-V.
- 464 [28] Lantz CA, Nebenzahl E. Behavior and interpretation of the κ statistic: Resolution of the two
 465 paradoxes. J Clin Epidemiol 1996;49: 431–4. doi: 10.1016/0895-4356(95)00571-4.
- 466 [29] Paul S, Toft N, Agerholm JS, Christoffersen AB, Agger JF. Bayesian estimation of sensitivity and
 467 specificity of Coxiella burnetii antibody ELISA tests in bovine blood and milk. Prev Vet Med
 468 2013;109: 258–63. doi: 10.1016/J.PREVETMED.2012.10.007.
- 469 [30] de Bronsvoort BMC, Bagninbom JM, Ndip L, Kelly RF, Handel I, Tanya VN, et al. Comparison of
 470 Two Rift Valley Fever Serological Tests in Cameroonian Cattle Populations Using a Bayesian
 471 Latent Class Approach. Front Vet Sci 2019;6: 258. doi: 10.3389/FVETS.2019.00258/BIBTEX.
- 472 [31] Emery MP, Ostlund EN, Schmitt BJ. Comparison of Q fever serology methods in cattle, goats,
 473 and sheep. J Vet Diagn Invest 2012;24: 379–82. doi: 10.1177/1040638711434943.

474 [32] Lurier T, Rousset E, Gasqui P, Sala C, Claustre C, Abrial D, et al. Evaluation using latent class
475 models of the diagnostic performances of three ELISA tests commercialized for the serological
476 diagnosis of Coxiella burnetii infection in domestic ruminants. Vet Res 2021;52. doi:
477 10.1186/S13567-021-00926-W.

- 478 [33] Package "vcd" Title Visualizing Categorical Data 2023. [cited 17 June 2024]. Available from:
 479 https://cran.r-project.org/web/packages/vcd/vcd.pdf
- 480 [34] Mariner J. Rift Valley fever surveillance. FAO Animal Production and Health Manual No. 21.
 481 Food and Agricultural Organizations of the United Nations (FAO). [cited 17 June 2024].
 482 Available from: https://openknowledge.fao.org/server/api/core/bitstreams/4052d2f0-88e5483 4a3f-9ae5-049d3c78413c/content
- Field PR, Mitchell JL, Santiago A, Dickeson DJ, Chan S-W, Ho DWT, et al. Comparison of a
 Commercial Enzyme-Linked Immunosorbent Assay with Immunofluorescence and
 Complement Fixation Tests for Detection of Coxiella burnetii (Q Fever) Immunoglobulin M. J
 Clin Microbiol 2000;38: 1645. doi: 10.1128/JCM.38.4.1645-1647.2000.
- Field PR, Santiago A, Chan SW, Patel DB, Dickeson D, Mitchell JL, et al. Evaluation of a novel
 commercial enzyme-linked immunosorbent assay detecting Coxiella burnetii-specific
 immunoglobulin G for Q fever prevaccination screening and diagnosis. J Clin Microbiol
 2002;40: 3526–9. doi: 10.1128/JCM.40.9.3526-3529.2002.

492 493 494	[37]	Sanz JC, De Los Ríos R, Martín F, Ángeles Tébar M, Jado I, Anda P. Aplicación de cuatro técnicas de ELISA (dos para IgM y dos para IgG) en el diagnóstico serológico de un brote de fiebre Q. Enferm Infecc Microbiol Clin 2006;24: 178–81. doi: 10.1157/13086551.
495 496 497	[38]	Healy B, Van Woerden H, Raoult D, Graves S, Pitman J, Lloyd G, et al. Chronic Q Fever: Different Serological Results in 3 Countries-Results of a Follow-up Study 6 Years After a Point Source Outbreak. Clin Infect Dis. 2011;52: 1013-1019. doi: 10.1093/cid/cir132.
498 499 500	[39]	Ferrara G, Colitti B, Pagnini U, Iovane G, Rosati S, Montagnaro S. Characterization of recombinant Ybgf protein for the detection of Coxiella antibodies in ruminants. Journal of Veterinary Diagnostic Investigation 2022;34: 646–53. doi: 10.1177/10406387221093581.
501 502 503	[40]	Gerlach C, Škultéty L, Henning K, Neubauer H, Mertens K. Coxiella burnetii immunogenic proteins as a basis for new Q fever diagnostic and vaccine development. Acta Virol 2017;61: 377–90. doi: 10.4149/AV_2017_320.
504 505	[41]	Lippi G, Von Meyer A, Cadamuro J, Simundic AM. Blood sample quality. Diagnosis (Berl) 2019;6: 25–31. doi: 10.1515/DX-2018-0018.
506 507 508	[42]	Lippi G, Plebani M, Di Somma S, Cervellin G. Critical Reviews in Clinical Laboratory Sciences Hemolyzed specimens: a major challenge for emergency departments and clinical laboratories 2011. doi: 10.3109/10408363.2011.600228.
509 510 511 512	[43]	Edouard S, Million M, Casalta JP, Collart F, Amphoux B, Raoult D. Low antibodies titer and serological cross-reaction between Coxiella burnetii and Legionella pneumophila challenge the diagnosis of mediastinitis, an emerging Q fever clinical entity. Infection 2017;45: 911–5. doi: 10.1007/S15010-017-1048-6.
513 514 515	[44]	La Scola B, Raoult D. Serological cross-reactions between Bartonella quintana, Bartonella henselae, and Coxiella burnetii. J Clin Microbiol 1996;34: 2270–4. doi: 10.1128/JCM.34.9.2270-2274.1996.
516 517	[45]	Lukacova M, Melnicakova J, Kazar J. Cross-Reactivity between Coxiella burnetii and Chlamydiae. Folia Microbiol 1999;44: 579–84. doi:10.1007/BF02816263.
518 519 520	[46]	Scott RM, Feinsod FM, Allam IH, Ksiazek,' TG, Peters CJ, Botros,' And BAM, et al. Serological Tests for Detecting Rift Valley Fever Viral Antibodies in Sheep from the Nile Delta. J Clin Microbiol 1986;24: 612–4. doi: 10.1128/jcm.24.4.612-614.1986.
521 522 523	[47]	Swanepoel R, Struthers JK, Erasmus MJ, Shepherd SP, Mcgillivray GM, Erasmus BJ, et al. Comparison of techniques for demonstrating antibodies to Rift Valley fever virus. J Hyg (Lond) 1986;97: 317–29. doi: 10.1017/S0022172400065414.
524 525 526	[48]	Szymczak MS, Reeves WK, Miller MM. Further Characterization of Rio Grande Virus and Potential for Cross Reactivity with Rift Valley Fever Virus Assays. Viruses 2021;13. doi: 10.3390/V13091719.
527 528 529	[49]	Edouard S, Mahamat A, Demar M, Abboud P, Djossou F, Raoult D. Comparison between emerging Q fever in French Guiana and endemic Q fever in Marseille, France. Am J Trop Med Hyg 2014;90: 915–9. doi: 10.4269/AJTMH.13-0164.
530 531 532	[50]	Tumusiime D, Isingoma E, Tashoroora OB, Ndumu DB, Bahati M, Nantima N, et al. Mapping the risk of Rift Valley fever in Uganda using national seroprevalence data from cattle, sheep and goats. PLoS Negl Trop Dis 2023;17: e0010482. doi: 10.1371/JOURNAL.PNTD.0010482.

533[51]Murphy AM, Field PR. The persistence of complement-fixing antibodies to q-fever (coxiella534burneti) after infection. Medical Journal of Australia 1970;1: 1148–50. doi: 10.5694/J.1326-5355377.1970.TB84481.X.

- 536 [52] Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus (Bunyaviridae:
 537 Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and
 538 prevention. Vet Res 2010;41. doi: 10.1051/VETRES/2010033.
- 539[53]Brown RD, Scott GR, Dalling T. Persistence of antibodies to rift valley fever in man. The Lancet5401957;270: 345. doi: 10.1016/S0140-6736(57)92243-2.
- 541 [54] Sukocheva OA, Marmion BP, Storm PA, Lockhart M, Turra M, Graves S. Long-term persistence
 542 after acute Q fever of non-infective Coxiella burnetii cell components, including antigens. QJM
 543 2010;103: 847–63. doi: 10.1093/QJMED/HCQ113.
- [55] Marmion BP, Sukocheva O, Storm PA, Lockhart M, Turra M, Kok T, et al. Review Q fever:
 persistence of antigenic non-viable cell residues of Coxiella burnetii in the host-implications
 for post Q fever infection fatigue syndrome and other chronic sequelae. QJM. 2009;102(10):
 673-684. doi:10.1093/qjmed/hcp077.
- 548 [56] Stellfeld M, Gerlach C, Richter IG, Miethe P, Fahlbusch D, Polley B, et al. Evaluation of the
 549 Diagnostic Potential of Recombinant Coxiella burnetii Com1 in an ELISA for the Diagnosis of Q
 550 Fever in Sheep, Goats and Cattle. Microorganisms 2020;8: 1–19. doi:
 551 10.3390/microorganisms8081235.
- 552 [57] Mehraj V, Textoris J, Capo C, Raoult D, Leone M, Mege JL. Overexpression of the per2 gene in
 553 male patients with acute Q fever. Journal of Infectious Diseases 2012;206: 1768–70. doi:
 554 10.1093/INFDIS/JIS600.
- 555 [58] Gay L, Melenotte C, Lopez A, Desnues B, Raoult D, Leone M, et al. Impact of Sex Hormones on
 556 Macrophage Responses to Coxiella burnetii. Front Immunol 2021;12: 5510. doi:
 557 10.3389/FIMMU.2021.705088/BIBTEX.
- Leone M, Honstettre A, Lepidi H, Capo C, Bayard F, Raoult D, et al. Effect of sex on Coxiella
 burnetii infection: protective role of 17beta-estradiol. J Infect Dis 2004;189: 339–45. doi:
 10.1086/380798.
- 561 [60] Schoffelen T, Wong A, Rümke HC, Netea MG, Timen A, van Deuren M, et al. Adverse events
 562 and association with age, sex and immunological parameters of Q fever vaccination in
 563 patients at risk for chronic Q fever in the Netherlands 2011. Vaccine 2014;32: 6622–30. doi:
 564 10.1016/J.VACCINE.2014.09.061.